In a significant move for the European life sciences sector, venture capital firm Forbion announced on Tuesday it has raised €2.3 billion (approximately $2.6 billion) for two new investment funds. The fundraise, the largest in the firm's 20-year history, injects substantial capital into a market that has recently faced significant headwinds and what industry figures describe as a general shortage of funding. The capital infusion solidifies Forbion's position as Europe's largest dedicated life sciences venture capital firm, bringing its total assets under management to roughly €7.5 billion.
The new capital is strategically divided between two distinct vehicles: Forbion Growth Opportunities Fund IV, aimed at later-stage companies, and Forbion Ventures Fund VIII, which targets a wider range of therapeutic ventures. According to the firm, this dual approach will allow it to finance approximately 30 high-potential companies. The successful fundraising, which Forbion stated substantially exceeded its target, signals strong investor confidence in the firm's strategy amidst a challenging environment for European venture capital.
Forbion's Dual Fund Strategy: A Guide for Biotech Founders
Forbion has structured its new capital across two funds with distinct mandates, providing clear avenues for biotech companies depending on their stage of growth and therapeutic focus. This separation allows the firm to apply different risk models and support structures tailored to companies at different points in their lifecycle, from new ventures to more mature biopharma enterprises. The firm’s official descriptions outline separate strategies for its later-stage growth fund and its more flexible ventures fund, allowing founders and management teams to identify which pool of capital aligns with their company's specific needs. This dual-fund model is a strategic response to the varied capital requirements within the life sciences ecosystem.
Early-stage ventures often require seed funding to validate novel science, while later-stage companies need substantial capital to fund expensive late-phase clinical trials and prepare for commercialization. By operating two specialized funds, Forbion can participate across this spectrum.
| Fund Name | Investment Focus | Target Company Stage | Geographic Scope |
|---|---|---|---|
| Forbion Growth Opportunities Fund IV | Biopharma companies developing novel therapies in areas of high medical need. | Later-stage companies. | Europe and North America. |
| Forbion Ventures Fund VIII | Therapeutics-focused biotech companies, including new ventures and existing businesses. | Various stages. | Not specified in announcement. |
Context: European Biotech's Persistent Capital Challenge
Forbion's successful capital raise comes at a critical time for the European venture landscape. The market has been widely characterized by a "general shortage of capital," creating a difficult environment for biotech companies seeking funding. According to an analysis citing PitchBook data, 2025 marked the worst year for European venture fundraising in a decade. This capital scarcity can stifle innovation, forcing promising startups to delay critical research, accept less favorable investment terms, or abandon projects altogether. While the market has shown signs of a rebound in 2026, the recovery has not been uniform. The same PitchBook data suggests the rebound has benefited seasoned, established firms more than newcomers.
A broader global report from Pitchbook noted that through the third quarter of 2026, venture capital firms have raised $142.1 billion and are on pace to exceed $200 billion for the full year. However, the report also indicated that more capital is being concentrated into fewer, larger funds. Forbion's raise, which it described as one of the largest in life sciences globally over the past five years based on Preqin data, positions it as a major recipient of this concentrated capital, highlighting a flight to quality among institutional investors.
Implications for Biotech Founders and Investors
The new funds provide Forbion with what its managing partner and co-founder, Sander Slootweg, called "significant dry powder." In a statement, Slootweg emphasized the strategic advantage this provides, noting the capital allows the firm "to select the most exciting biotech companies for investment" in a market where funding is otherwise scarce. With the capacity to finance approximately 30 portfolio companies across the two funds, Forbion is now one of the most significant sources of capital for the European and North American life sciences sectors. For biotech founders, this development presents both an opportunity and a challenge.
The existence of such a large, dedicated pool of capital is a positive signal for the health of the industry. The clear distinction between the growth and ventures funds also provides a roadmap for companies to approach Forbion. However, with more capital concentrated in a single firm, the selection process is likely to be highly competitive. Forbion's ability to be selective means it will likely focus on companies with what it deems to be the most promising assets and proven teams, raising the bar for those seeking investment.
Forbion's Position and Future Outlook
With this €2.3 billion fundraise, Forbion has not only secured its own future but has also reinforced its influence over the direction of European biotech. As the continent's largest dedicated life sciences VC, its investment decisions will help shape which therapeutic areas and technologies receive crucial funding and support. The firm's ability to deploy capital from both a ventures and a growth fund gives it the capacity to support companies from their inception through to maturity, a key advantage in the long and capital-intensive process of drug development. The firm is not waiting to deploy its new resources.
In its announcement, Forbion confirmed that the first investments from both the Growth Opportunities Fund IV and Ventures Fund VIII have already been completed. This indicates a rapid pace of deployment, aiming to capitalize on opportunities in the current market. The firm's ability to act decisively with its substantial "dry powder" gives it a powerful negotiating position and the ability to lead large, syndicated financing rounds that might otherwise be difficult to assemble in the current climate.
What This Means for European Biotech: A Signal of Renewed Investment
Forbion's record fundraise serves as a powerful counter-signal to the recent narrative of capital scarcity in European life sciences. While the broader market may still face challenges, the success of this raise demonstrates that institutional investors retain a strong appetite for the sector when presented with an experienced management team and a clear strategy. It suggests a bifurcation in the market, where top-tier firms can attract significant capital while others may continue to struggle. For biotech founders and investors, the immediate takeaway is the emergence of a well-defined and substantial new source of funding. The key is to understand the distinct mandates of Forbion's two new funds.
Biotech founders and investors should assess their company's stage and therapeutic focus to identify alignment with Forbion's distinct fund strategies. The tangible impact of this capital injection will become clearer over the coming months, and the measurable indicator of its effect on the ecosystem will be to monitor the announcement of new portfolio companies and investment rounds from Forbion's two new funds.
